In a clinical context, this study identifies hopeaphenol as a promising therapeutic candidate for cardiac hypertrophy, emphasizing the significance of the AMPK/SIRT1 signaling pathway in ameliorating myocardial metabolic disorders. This evidence concerns the gene SIRT1 and cardiac hypertrophy.